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ABSTRACT
We describe two unrelated women who in their fifth decade developed a severe disorder characterized by large joint osteonecrosis
and multiple minimal trauma fractures in both the axial and appendicular skeleton, including unusual metaphyseal fractures of the
proximal tibia. Bone density testing showed borderline osteoporosis of the spine and osteopenia of the femur. Therapy with bispho-
sphonates and teriparatide failed to prevent further fractures. To our knowledge, this disorder has not been described previously.
Investigations to date, including a genetic screen, have not revealed its cause. © 2020 The Authors. JBMR Plus published byWiley Peri-
odicals, Inc. on behalf of American Society for Bone and Mineral Research.
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Introduction
Osteonecrosis (avascular necrosis) of long bones is mostcommonly associated with trauma or prolonged high-dose
steroid use, particularly in the context of lupus, human immunode-
ficiency virus infection, bone marrow transplantation, or solid
organ transplantation. Other causes include sickle cell disease,Mor-
quio syndrome, and Gaucher disease.(1) Idiopathic osteonecrosis is
rare, but has been associated with thrombophilic disorders and
alcohol dependence. We describe two unrelated women who in
their fifth decade developed a severe bone disorder characterized
by both osteonecrosis and multiple osteoporotic fractures. To our
knowledge, this appears to be a novel disorder.
Patients and Methods
Case histories
Subject A
At the age of 42 subject A, who was of European descent, pre-
sented with a rib fracture and shortly after, a vertebral fracture.
Osteoporosis was diagnosed and i.v. pamidronate treatment
was started. In the next 3 years she developed, in rapid succes-
sion, osteonecrosis of both hips and her right humeral head.
Over the following 10 years, despite continued treatment with
various bisphosphonates, she sustained multiple long bone,
metatarsal, pubic, rib, and vertebral fractures after minimal
trauma (see Fig. 1 for chronology). The tibial fractures were
unusual, occurring through the metaphyseal region. At the age
of 55 she developed osteonecrosis of the left humeral head
and had joint replacement surgery.
She had sustained one fracture as a 9-year-old, but otherwise
had no significant past medical history. She had one uneventful
pregnancy. She had never smoked. There was no history of an
eating disorder. Her BMI at presentation was 19.6 kg/m2. She
had been of normal stature (1.62 m), but by age 55 had lost
15 cm of height through multiple vertebral fractures. She
reached menopause at the age of 53. There was no history of
bone disease in her parents or siblings. She had no dysmorphic
features or signs of osteogenesis imperfecta or cortisol excess.
She had no history of thromboembolic disease. At age 43 she
was recognized to have mild dyslipidemia; she was taking a
low dose of atorvastatin to bring her cholesterol level to normal.
Her alcohol intakewasmoderate. At age 63 she is ambulant with-
out assistance, but restricted in walking longer distances and
activities that involve raising the arms above shoulder level.
Subject B
At the age of 44 subject B, who was also of European descent,
developed metatarsal fractures. The following year she experi-
enced sudden onset of pain in the right groin. Radiographs
showed disintegration of the femoral head, most likely caused
by avascular necrosis, and she had a hip joint replacement. Just
a few months later she experienced severe pain on the left side
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with similar findings on radiography, and again required hip joint
replacement surgery (see Fig. 1 for chronology). She took alen-
dronate from age 50 and remained reasonably well until age
53, when she developed sudden pain below the left knee. Radi-
ography showed a metaphyseal fracture, causing the leg to
bow outwards. Surgical treatment with an upper tibial osteot-
omy was undertaken. Shortly afterward, she developed sudden
onset of similar pain just below the right knee. After 6 weeks
the pain settled, but there was outward bowing of the right leg.
Just over a year later the pain worsened and she was unable to
weight-bear. She subsequently had an osteotomy and repair
through what was presumed to be a fracture that had healed
with deformity. Spine radiographs at age 55 showed vertebral
fractures. She later broke both distal femurs and suffered a peri-
prosthetic femoral fracture on the left.
She reported no childhood fractures, and therewas no family his-
tory of fracture or bone disease. She had an inguinal hernia repair at
the age of 8 and an appendicectomy at the age of 9. She had three
uneventful pregnancies. She smoked until the age of 45. There was
no history of an eating disorder. Her BMI at presentation was
22.0 kg/m2.Dyslipidemia (total cholesterol = 9.7 mmol/L)was recog-
nized at age 46, but she declined statin therapy until age 52. At the
age of 50, she had a hysterectomy, oophorectomy, and temporary
defunctioning colostomy for sepsis related to a tubo-ovarian
abscess. She had no history of thromboembolic disease. She had
been of normal stature (1.61 m) prior to the onset of vertebral frac-
tures, but between the ages of 48 and 64 she lost 5 cm of height.
She had nodysmorphic features or signs of osteogenesis imperfecta
or cortisol excess. Her alcohol intake was moderate. At the age of
65 she remains ambulant and manages all her activities of daily liv-
ing, but slowly and carefully.
Results
Laboratory investigations
Basic hematological and biochemical investigations (including
renal function, thyroid function, plasma calcium, phosphate,
calcidiol, PTH, alkaline phosphatase (ALP), and liver enzymes
(including gamma-glutamyl transpeptidase) were normal in
both subjects. Bone resorption markers prior to bisphosphonate
treatment were not measured. Biochemical testing for Cushing
syndrome was negative. Gaucher disease was excluded by the
finding of normal leukocyte β-glucocerebrosidase activity
(Table 1). Systemic mastocytosis, myeloma, celiac disease, and
antiphospholipid syndrome were excluded by appropriate test-
ing. Antinuclear antibodies were negative. Plasma homocysteine
(measured only in subject B) was normal.
Radiology
The long bone cortices of subject A were thin, but there were
no Looser zones. Almost all the thoracic vertebras showed
grade 2 or grade 3 fractures at the time of the most recent
imaging. Her humeral heads, femoral heads, and tibial plateaus
were deformed, and there were signs of past metatarsal, pubic,
clavicular, and rib fractures (Figures 2A-G). On review at age
55, subject B had several vertebral compression fractures. The
long bones showed thin cortices and spotty osteoporotic
changes. There were healing fractures of the inferior ischiopu-
bic rami and lateral bowing of the tibia and fibula, particularly
distally. The bones in the feet had thin cortices, with evidence
of previous metatarsal fractures (Figures 3A-F). Skull radio-
graphs were normal in both subjects. A bone scintiscan (subject
B) showed increased isotope uptake in all the areas affected by
recent lesions, but no other abnormalities.
Bone densitometry
Both women had bone density measurements before starting
bisphosphonate treatment. The results were similar with border-
line osteoporosis at the lumbar spine and osteopenia at the fem-
oral neck. The respective T-scores were A (age 42): −2.5 and
− 1.3; B (age 45): −2.4 and −1.6.
Fig. 1. Timeline to indicate age at occurrence of fractures and episodes of osteonecrosis and treatment periods in subjects A (upper panel) and B (lower
panel). M = time of menopause; Bx = time of bone biopsy; Iban = ibandronate treatment; Rise = risedronate treatment; TPT = teriparatide treatment.
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Bone biopsy
The femoral head from subject B excised at age 45 showed disor-
ganization of the chondro-osseous junctionwith fibrous granula-
tion tissue, necrotic bone, and new bone formation. The features
were consistent with avascular necrosis.
Transiliac bone biopsies from both subjects were taken and
undecalcified sections prepared. Compared with published nor-
mal values,(2) both showed thin cortices, increased cortical
porosity, and low trabecular bone volume, but no signs of osteo-
malacia. In both cases, bone turnover appeared low, but the
biopsies had been obtained after 5 years of bisphosphonate
Table 1. Biochemical Findings
Subject A
Normal values/
units Subject B Normal values/units
Alkaline phosphatase 41a 30 to 120 U/L 81 30 to 120 U/L
β-glucocerebrosidase activity 4.41 μmol/L/h 1 to 5 μmol/L/h 945 pmol/min/mg protein 600 to 3200 pmol/min/mg
protein
Cushing syndrome screening 9 a.m. plasma
cortisol
210 nmol/L
110 to 550 nmol/L 9 a.m. plasma cortisol
348 nmol/L
With normal diurnal
variation
110 to 550 nmol/L
Homocysteine - - 7.5 μmol/L 5 to 15 μmol/L
aResult obtained on bisphosphonate treatment.
Fig. 2. Selected radiographs from subject A. (A,B) Radiograph and MRI illustrating osteonecrosis of the shoulder, (C) metatarsal fractures (arrows), (D)
osteonecrosis of the femoral head, (E) multiple vertebral fractures (MRI), (F) patellar fracture, also showing spotty osteoporosis of the upper tibia, and
(G) submetaphyseal tibial fracture (arrow). The subject’s age at the time of each radiograph is indicated.
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treatment. There was no histological evidence of systemic
mastocytosis.
Formal quantitation was undertaken only in subject B’s
biopsy. The trabecular bone volume was reduced and trabecular
thickness low. The cortical bone showed increased cortical
porosity. Trabecular osteoid was reduced (Table 2). Few osteo-
blasts were observed. A short length of tetracycline double-
labeling was seen in cortical bone, but none was seen in
trabecular bone.
Genetic screening
Screening for mutations in 29 genes associated with bone fragil-
ity was undertaken using a next-generation sequencing plat-
form. Genomic DNA from leukocytes of subject A was enriched
with SureSelectXT Low Input Human All Exon V7 (Agilent Tech-
nologies, Santa Clara, CA, USA) followed by sequencing on a
HiSeq 3000 platform (Illumina, San Diego, CA, USA). The genes
examined were: ACAN, ALPL, B3GALT6, BMP1, COL1A1, COL1A2,
CREB3L1, CRTAP, FAM46A, FKBP10, IFITM5, LEPRE1, LRP5, LRP6,
MBTPS2, NBAS, P4HB, PLOD2, PLS3, PPIB, SEC24D, SERPINF1,
SERPINH1, SP7, SPARC, TAPT1, WNT1, TMEM38B, and LIFR. No path-
ogenic variants were detected, though the technique used is less
sensitive for detecting deletions and duplications >15 bp, repeat
expansions, and copy number variants.
Fig. 3. Selected radiographs from subject B. (A) Bilateral hip joint replacements after osteonecrosis of the hips, (B) bilateral osteotomy repairs for subme-
taphyseal tibial fractures, (C) vertebral fractures, (D) spotty osteoporosis of the distal radius and ulna, (E) healingmetatarsal fractures (arrows), and (F) distal
femoral fracture. The subject’s age at the time of each radiograph is indicated.
Table 2. Quantitative Bone Histology From Subject B at Age 55
Parameter Result
Normal
values(2)
Trabecular bone volume BV/TV 11.0% 22.5  3.5
Cortical thickness Ct.Th 567
μm
909  98
Cortical porosity Ct.PO 17.2% 6.3  0.6
Trabecular osteoid
volume
OV/BV 0.6% 1.9  0.4
Trabecular osteoid
thickness
O.Th 2.05
μm
9.5  0.6
Trabecular eroded
surface
ES/BS 5.4% 5.1  0.6
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Response to treatment
Both patients had intensive bisphosphonate treatment (see
Fig. 1), but continued to fracture. Both were subsequently trea-
ted with an 18-month course of teriparatide injections, but again,
fractures continued to occur. Subject A was also treated with
alfacalcidol while taking bisphosphonates, but this was discon-
tinued during teriparatide treatment because of hypercalcemia.
Bisphosphonate treatment was given after teriparatide to
subject A, but subject B declined further treatment. With teri-
paratide treatment, the bone formation markers ALP and
procollagen-1 N-propeptide increased as expected in subject A
(data for subject B incomplete).
As indicated above and in Fig. 1, fractures continued despite
bisphosphonate and teriparatide treatment. In subject A sequen-
tial measures of spinal bone density were difficult to interpret
because of progressive vertebral deformities, but the femoral
neck bone density T-score fell between the ages of 48 and
65 from −1.3 to −2.6. In subject B, sequential measures of bone
density were not possible because of hip replacement surgery
and progressive vertebral deformities, but the forearm bone
density T-score fell between the ages of 53 and 59 from −1.2
to −4.1.
Discussion
To our knowledge this disorder of osteoporosis with osteonecro-
sis has not been described previously. The two women, who
were unrelated and had no occupational exposure to toxins,
had strikingly similar clinical presentations with fractures and
osteonecrosis of the hip joints that began in their mid-40s,
before menopause. In both, fractures of the long bones and ver-
tebra and further osteonecrosis episodes continued despite
therapy with bisphosphonates, and later, teriparatide. Bone den-
sity testing close to the onset of the illness showed borderline
osteoporosis at the lumbar spine and osteopenia at the femoral
neck, but despite intensive therapy with bisphosphonates bone
loss occurred during follow-up. The femoral fractures sustained
by subject B did not meet the criteria for bisphosphonate-related
atypical femur fractures, as suggested by the ASBMR taskforce.(3)
Both women sustained fractures of the proximal tibial meta-
physes. Metaphyseal fractures of this type (41-A2/A3 in the AO
classification) are rare, comprising only 3% of tibial fractures.(4)
The majority occurs after trauma in men under the age of
40, so apparently spontaneous fractures in women are excep-
tional, and in our cases it is possible that the osteonecrotic pro-
cess underlay these fractures.
The bone biopsies, taken after bisphosphonate treatment,
showed osteoporosis with no sign of osteomalacia, and gave
no pathological clues. The conditions most commonly linked to
both osteoporosis and osteonecrosis are sickle cell disease,
Cushing syndrome, and Gaucher disease. Neither subject had
clinical evidence of sickle cell disease, cortisol excess, nor was
taking exogenous steroids. Though usually diagnosed earlier in
life, Gaucher disease can present in the fifth decade, but neither
woman had anemia, splenomegaly, or Erlenmeyer flask deformi-
ties of the femurs, and both had negative biochemical tests for
this disorder. Of note, both women had high-serum cholesterol
(severe in subject B). There is anecdotal data that hyperlipidemia
might be a risk factor for the development of osteonecrosis in
children with acute lymphoblastic leukemia(5) and that statin
therapy might lower the risk of osteonecrosis in people treated
with corticosteroids.(6) However, neither osteoporosis nor osteo-
necrosis are associated with familial hyperlipidemia, suggesting
that the latter alone is unlikely to explain the disorder we
describe.
The lack of response to bisphosphonate therapy and contin-
ued fractures with osteonecrosis suggests perhaps osteoblast
or osteocyte failure, although fractures did seem to heal. Neither
subject had a family history of any similar disorder, and whether
this is an acquired condition or genetic we do not know. How-
ever, it would be unusual for a genetic bone disorder to present
for the first time this late in life, and in one subject screening of
29 genes known to be associated with bone fragility was nega-
tive. We would be interested to hear from other clinicians who
have seen similar cases.
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